MassHealth Cuts GLP-1 Coverage for 22,000 Residents, Saving Massachusetts $15 Million a Year
Updated
Updated · Fortune · Jul 23
MassHealth Cuts GLP-1 Coverage for 22,000 Residents, Saving Massachusetts $15 Million a Year
1 articles · Updated · Fortune · Jul 23
Summary
MassHealth this month stopped covering GLP-1 drugs, a change affecting 22,000 Massachusetts residents as the state seeks to curb spending.
GLP-1 costs have surged more than 500% from 2019 to 2024, and broader demand is still rising as U.S. use is projected to reach 25 million people by 2030 from 10 million in 2025.
That cost pressure is spreading beyond Massachusetts: Cigna last month ended GLP-1 access for its employees, and 10% of employers that now cover weight-loss GLP-1s plan to drop them by 2027.
The pullback comes as obesity and chronic disease remain widespread in the U.S., where 76.4% of adults have at least one chronic condition and 51.4% have two or more.
As insurers slash GLP-1 coverage to save millions, could this targeted approach actually trigger a massive healthcare crisis of untreated chronic diseases?
With bariatric surgeries dropping and GLP-1 costs exploding, what happens to millions of patients when employers abruptly cut off their weight-loss lifelines?
If stopping GLP-1s guarantees weight regain, are new targeted Medicare policies a sustainable cure or just a temporary financial band-aid?